Cardarine vs Stenabolic: A Detailed Comparison

Cardarine (GW-501516) and Stenabolic (SR9009) are often compared in performance-related research discussions, but neither is a selective androgen receptor modulator (SARM). This comparison describes their research backgrounds; it does not recommend either compound for human use.

What Was Cardarine Designed To Do?

Developed by GlaxoSmithKline, Cardarine acts as a PPARδ agonist. Cardarine advanced to clinical trials but was discontinued due to safety concerns. Its mechanism involves activating the PPARδ pathway, which plays a vital role in energy use and fat metabolism.

What Was Stenabolic Designed To Do?

Stenabolic functions as a REV-ERB agonist and remains in preclinical research. Stenabolic influences the body's internal clock, thereby affecting energy production and overall metabolism.

Key Differences

Aspect	Cardarine	Stenabolic
Compound Class	PPARδ Agonist	REV-ERB Agonist
Mechanism	Lipid-metabolism research	Circadian-metabolism research
Clinical Progression	Reached and discontinued in trials	Stays at preclinical stage
Human Data	Data from halted trials	Limited to animal studies

What Actually Separates Them?

The primary distinction between Cardarine and Stenabolic is their clinical development status. Cardarine proceeded to human trials but was eventually stopped, while SR9009 has not moved beyond animal research.

Research-only supply and legal context

Supplied for research purposes only. Not for human or veterinary use and not intended for consumption. Research findings do not establish safety or justify personal use. No dosage, cycle or administration guidance is provided.

Consult the Global Legality Guide and applicable local rules. Product documentation is available through our Lab Analysis page.